Ampio Pharmaceuticals Inc

ASE:AMPE   1:25:19 PM EDT
-0.05 (-2.82%)
Products, Regulatory

Ampio Reports Top-line Results from Study of Ampion in Adult Patients With Severe Osteoarthritis of Knee

Published: 09/15/2021 13:26 GMT
Ampio Pharmaceuticals Inc (AMPE) - Ampio Pharmaceuticals Announces Top-line Results From Ap-013 Phase Iii Study of Ampion in Adult Patients Suffering From Severe Osteoarthritis of the Knee (oak).
Ampio Pharmaceuticals - Ampion Demonstrated Statistically Significant Reduction in Pain and Improvement in Function at 12 Weeks in Severe Oak Patients.
Ampio Pharmaceuticals - Results Reflect Strong Safety Profile With No Treatment Related Serious, Material Adverse Events.
Ampio Pharmaceuticals - Current Cash Runway of About 12 Months Expected to Provide Sufficient Near-term Liquidity, Flexibility to Support Business Operations.
Ampio Pharmaceuticals Inc - Plans to Meet With FDA to Discuss Phase Iii Results and Biologics License Application.